Novo Nordisk partners with OpenAI in weight loss drug race

Novo Nordisk, a Danish pharmaceutical company known for its weight-loss drugs Ozempic and Wegovy, has partnered with OpenAI to leverage AI technology in its operations. The collaboration aims to analyze complex datasets and identify promising drug candidates to stay competitive in the expanding obesity drug market.